Next Article in Journal
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions
Next Article in Special Issue
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
Previous Article in Journal
Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications
Previous Article in Special Issue
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Open AccessReview

Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore

by 1 and Shirley ShiDu Yan 1,2,3,*
1
Department of Surgery, Physicians & Surgeons College of Columbia University, New York, NY 10032, USA
2
Department of Pathology & Cell Biology, Physicians & Surgeons College of Columbia University, New York, NY 10032, USA
3
The Taub institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY 10032, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(6), 1936-1948; https://doi.org/10.3390/ph3061936
Received: 10 May 2010 / Revised: 10 June 2010 / Accepted: 14 June 2010 / Published: 14 June 2010
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
Mitochondrial dysfunction occurs early in the progression of Alzheimer’s disease. Amyloid-β peptide has deleterious effects on mitochondrial function and contributes to energy failure, respiratory chain impairment, neuronal apoptosis, and generation of reactive oxygen species in Alzheimer’s disease. The mechanisms underlying amyloid-β induced mitochondrial stress remain unclear. Emerging evidence indicates that mitochondrial permeability transition pore is important for maintenance of mitochondrial and neuronal function in aging and neurodegenerative disease. Cyclophilin D (Cyp D) plays a central role in opening mitochondrial permeability transition pores, ultimately leading to cell death. Interaction of amyloid-β with cyclophilin D triggers or enhances the formation of mitochondrial permeability transition pores, consequently exacerbating mitochondrial and neuronal dysfunction, as shown by decreased mitochondrial membrane potential, impaired mitochondrial respiration function, and increased oxidative stress and cytochrome c release. Blockade of cyclophilin D by genetic abrogation or pharmacologic inhibition protects mitochondria and neurons from amyloid-β induced toxicity, suggesting that cyclophilin D dependent mitochondrial transition pores are a therapeutic target for Alzheimer’s disease. View Full-Text
Keywords: amyloid beta; mitochondrial permeability transition; cyclophilin D; therapy amyloid beta; mitochondrial permeability transition; cyclophilin D; therapy
Show Figures

Figure 1

MDPI and ACS Style

Du, H.; ShiDu Yan, S. Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore. Pharmaceuticals 2010, 3, 1936-1948.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop